Millennium Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.4M Buy
50,500
+14,500
+40% +$7.66M 0.01% 1435
2026
Q2
$19.3M Buy
+36,000
New +$18.4M 0.01% 1659
2024
Q3
– Sell
-15,700
Closed -$4.4M – 6326
2024
Q2
$4.4M Buy
15,700
+14,800
+1,644% +$3.52M ﹤0.01% 2843
2024
Q1
$240K Sell
900
-600
-40% -$141K ﹤0.01% 5271
2023
Q4
$347K Sell
1,500
-8,200
-85% -$1.43M ﹤0.01% 4883
2023
Q3
$1.42M Buy
9,700
+7,800
+411% +$1.47M ﹤0.01% 3896
2023
Q2
$439K Sell
1,900
-15,700
-89% -$4.25M ﹤0.01% 4633
2023
Q1
$4.26M Sell
17,600
-37,700
-68% -$10.3M ﹤0.01% 2753
2022
Q4
$16.1M Buy
+55,300
New +$5.41M 0.01% 1648
2019
Q1
– Sell
-12,500
Closed -$1.41M – 4178
2018
Q4
$1.41M Hold
12,500
– – ﹤0.01% 2413
2018
Q3
$2.68M Buy
+12,500
New +$3.14M ﹤0.01% 2224

Other funds holding MDGL

Millennium Management's MDGL Position: Q3 2026 in Review

Millennium Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 90% in Q3 2026, selling an estimated $38.5M and leaving 8,295 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3237.

Millennium Management first reported a position in MDGL in Q2 2013 and has held it in 41 quarters since. The position peaked at $43.6M in Q2 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Millennium Management held 8,295 shares of Madrigal Pharmaceuticals worth $4.18M as of Q3 2026.
  • Millennium Management sold 72,901 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $38.5M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #3237 holding.
  • Millennium Management first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Millennium Management's Madrigal Pharmaceuticals position peaked at $43.6M in Q2 2026.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.